Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies

First Affiliated Hospital of Wenzhou Medical University300 enrolled

Overview

Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with systemic therapy, such as interventional therapy, targeted therapy, chemotherapy and immunotherapy and so on.

By tracking the short-term and long-term results of HCC patients treated with systemic therapy,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatments was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.All implementation details are based on the newest EuropeanWorking Group on Sarcopenia in Older People(EWGSOP) definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatments was explored.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Hepatocellular Carcinoma Sarcopenia

Interventions

Diagnostic Test: gait speed; ct scan; grip strength and chair stand testDIAGNOSTIC_TEST

The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical diagnosis of hepatocellular carcinoma * No cancer other than liver cancer has been diagnosed * Age ≥18 years * child-pugh score≤7 Exclusion Criteria: * uncompleted standard tests and questionnaires * received other therapies * Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) * Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3) * lost follow-up

Locations (1)

Gang Chen

Wenzhou, Zhejiang, China

Outcomes

Primary Outcomes

complications

The complications were classified according to the Clavien-Dindo classification, such as hypertension, fever, abdominal pain and so on.

Time frame: 3 months

overall survival

Overall survival was defined as the time from initiation of lenvatinib to death for any reason.

Time frame: 2 years

progression free survival

Progression free survival was defined as the time from initiation of lenvatinib to first progression or death.

Time frame: 2 years

Secondary Outcomes

Hospital stay

The time that patients spent in the hospital was recorded.

Time frame: 3 months

Hospital cost

Hospital cost that patients spent was recorded.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.